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ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic
has come with many challenges for healthcare
providers and patients alike. In addition to the direct
burden it has placed on societies and health systems, it
had a significant impact in the care of patients with
chronic diseases, as healthcare resources were
deployed to fight the crisis, and major travel and social
restrictions were adopted. In the field of rheumatology,
this has required notable efforts from departments and
clinicians to adapt to the novel status quo and assure
the follow-up of patients with rheumatic and
musculoskeletal diseases. In the present viewpoint, we
provide a practical approach to tackle this reality. Key
measures include setting up preventive team
management strategies, optimising communication with
patients and reorganising patient care in all its
dimensions. We then anticipate the nuances of
rheumatology practice as restrictive measures are
progressively lifted, while an effective vaccine is still
pending. This includes the need to reimpose the same
strategy as further waves unfold. Finally, we look ahead
and address the lessons we can incorporate into post-
COVID-19 rheumatology.
INTRODUCTION
In the last 3 months, societies worldwide have
undergone major transformations to meet the
challenges posed by the coronavirus disease
2019 (COVID-19) pandemic.1 2 Particular
strain was put on healthcare systems, which
had to adapt to the dramatic rise in demand,
by increasing response capacity and prioritis-
ing assistance to patients with COVID-19. This
was instrumental in reducing direct mortality,
alongside with the implementation of travel
restriction and social isolation measures.3 4
However, it has also generated significant diffi-
culties in the care of patients with other acute
and chronic conditions, the extent of which is
only now starting to be appreciated.5–7 In par-
ticular, patients with rheumatic and musculos-
keletal diseases (RMDs) are at risk of having
their follow-up compromised, which might
translate into future complications, due to
uncontrolled disease and undetected serious
adverse effects of ongoing treatments.8 9 To
face this and respond to patient needs, rheu-
matology departments have to quickly respond
to the changing scenario and readapt their
organic structure.9 This requires noteworthy
adaptive capacity from all stakeholders and
active, creative planning to safeguard both
patients and healthcare workers (HCWs).
It is thus important to reflect on the various
aspects of reorganising rheumatology care to
keep it running during the COVID-19 pan-
demic (figure 1). This extends from the
initial suspension of non-urgent medical
appointments, substituted as much as possi-
ble by teleconsultation, to the following
months of progressive increase in selected
face-to-face visits, while dealing with the per-
sistence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in the
community. Herein, we detail a practical
approach to this problem, mainly based on
our experience at a large tertiary university
hospital. First, we focus on general measures
to manage and protect HCWs, and on the
importance of clear communication with
patients. Second, we propose a model to
reorganise RMD patient care across all its
dimensions. Third, we address the ‘day-
after’, projecting how can rheumatology
practice and research adapt as restrictions
are progressively waived, natural herd immu-
nity slowly expands and widespread vaccina-
tion is still not available. Finally, we look
ahead, focusing on the lessons learnt that
we can incorporate into post-COVID-19
rheumatology. Due to the variability of the
pandemic, resources and guidance across
countries, the concepts here discussed are
best seen as a framework aimed at clinicians
and departments involved in the care of
patients with RMDs, who can adapt it to
best fit their specific reality.
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IMMEDIATE RESPONSE TO LOCKDOWN
With a few exceptions, the initial response to the pan-
demic across the globe has generally included a more or
less strict societal lockdown. This necessarily led to major
adaptations in healthcare in general, and rheumatology
practice in particular. While uncertain, future similarly
restrictive lockdowns are a possibility, as potential surges
in contagion ensue at the local, regional, or national
level. In this event, implementation of comparable adjust-
ments to patient care is expected to be required.
General measures and team management
Careful teammanagement is a key element of the reorga-
nisation response. Redistribution of HCWs in a rotative
manner can be adopted, to assure the existence of backup
elements at all times. This allows swift replacement of
SARS-CoV-2-infected HCWs while promoting mental/
physical recovery in this stressful context.10 11 Particular
care may be employed with HCWs with clinical risk fac-
tors. Remote work (eg, administrative tasks, phone con-
sultation, digital prescription) is a useful alternative
whenever possible (eg, secure virtual private networks),
with on-site support by a minimal number of staff.
Depending on local/regional demands to reallocate
resources to COVID-19-dedicated services, residents and
younger specialists may be directly redeployed to these
activities or remain as a COVID-19-specific reserve. It is
important that this set-up remains fluid enough to natu-
rally accommodate the dynamics of the pandemic and
allow team redesign on a frequent basis.
Following local recommendations, universal surgical
mask use and reinforcement of cornerstone protective
gestures (eg, hand hygiene, social distancing) are funda-
mental in a hospital setting.12–15 This is particularly rele-
vant among HCWs, as in-hospital transmission is now
a recognised major issue.15–17 Other measures to be con-
sidered include frequent disinfection of common spaces
and objects (eg, doorknobs, mouse, keyboard, desks),
room ventilation improvement, and daily change of per-
sonal or medical clothing.12
Compliance with local occupational health guidance on
symptommonitoring and testing of HCWs is needed. Test-
ing strategies for SARS-CoV-2 by reverse transcription PCR
(RT-PCR) vary among countries and clinical settings,
depending on aspects such as type/duration of contact,
local incidence, testing capacity and cost. Considering the
transmission dynamics of SARS-CoV-2 (occurring at least
2–3 days before symptoms),18 the increasingly recognised
importance of asymptomatic disease (40–50%)19 and the
hazardous consequences of widespread contagion among
HCWs and patients, proactive and assertive screeningmea-
sures are warranted in a healthcare setting.16 This includes
testing symptomatic HCWs and quarantining direct close
professional (if clinical workload allows) and personal
Figure 1 Reorganisation of rheumatology care during the COVID-19 pandemic. Sequential steps of organising rheumatology
care throughout the coronavirus disease 19 (COVID-19) pandemic. Phase I addresses the initial response to the context of
widespread community transmission of SARS-CoV-2, with major travel and social restrictions. Phase II refers to the
adaptation taking place over the following months, as restrictions are slowly lifted and an effective vaccine is not yet
available. Finally, phase III anticipates the prospect of post-COVID-19 rheumatology. AE, adverse effects; bDMARDs,
biologic disease-modifying anti-rheumatic drugs; DMARDs, disease-modifying anti-rheumatic drugs; HCW, healthcare
worker; IV, intravenous; PPE, personal protective equipment; SARS-CoV-2, severe acute respiratory syndrome coronavirus
2; sc, subcutaneous; tsDMARDs, targeted synthetic disease-modifying anti-rheumatic drugs; VPN, virtual private network.
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contacts of confirmed cases. When feasible, extending
testing to HCWs and patients exposed to viral-positive sub-
jects would be preferable, to account for pre/asympto-
matic carriers.20
Infected HCWs undergo self-isolation and distance
monitoring for signs of severe disease by health authori-
ties, occupational health and infectious disease
specialists.12 21 22 Additional follow-up by a department
colleague might be helpful, can facilitate early detection
of complications or arrangement of physical observation,
and allows tracking of the team’s working capacity.
Return to work is advisable only after complete symptom
resolution and negative RT-PCR testing.21–23 Due to
delayed viral clearance (median time to negative test
20 days),24 25 confirmation testing is worthwhile
3–7 days after the disappearance of fever.21–23 Repeated
testing is often necessary,24 26 requiring teams to be pre-
pared for frequent adjustments in work planning.
Communicating with patients
Assuring frank, accurate communication with patients is
another crucial step. Patients with RMDs are likely to be
anxious and need to feel supported by their assisting
rheumatologists. As recently recognised in the European
League Against Rheumatism (EULAR) provisional
recommendations,20 there is currently no data to support
that patients with RMDs, including those treated with
disease-modifying anti-rheumatic drugs (DMARDs),
have increased susceptibility to SARS-CoV-2 or a worse
prognosis if infected.27–29 The reported higher overall
risk of patients with systemic inflammatory RMDs to
some infections (including viral infections)30–33 cannot,
at the moment, be assumed for COVID-19. This message
should be clearly conveyed to patients, who are advised to
follow the same guidance as for the general population
and patients without RMDs.20 Further, it is important to
liaise with family practitioners, who also play an essential
role in counselling and managing RMD patients.
It is worth mentioning, though, that patients with RMDs
often have concomitant poor prognostic factors for COVID-
19, such as advanced age (eg, those with osteoarthritis,
pseudogout, giant cell arteritis), male sex (eg, those with
gout), cardiovascular disease (eg, those with rheumatoid
arthritis, systemic lupus erythematosus) or metabolic syn-
drome (eg, thosewith gout, psoriatic arthritis).24 34–37More-
over, moderate-to-high-dose glucocorticoid usage, frequent
in patients with connective tissue diseases (CTDs) and vas-
culitis, increases the risk of hospitalisation.28 In turn,
tumour necrosis factor inhibitors have been associated
with decreased odds of hospitalisation28 and, although evi-
dence is overall weak, certain drugs have been used in
specific stages of the infection, including tocilizumab,38 39
anakinra,40 baricitinib,41 immunoglobulin,42 chloroquine/
hydroxychloroquine,43 colchicine44 and glucocorticoids.45
Despite early suggestions,46 there is also no clear data to
support a deleterious effect of nonsteroidal anti-
inflammatory drugs.47 It remains plausible, nonetheless,
that some of these treatments can mask initial symptoms,
delay diagnosis and confound the interpretation of
a serious clinical complication of COVID-19.
Current recommendations advise patients with RMD to
maintain their treatments.20 48 49 If possible, increases in
glucocorticoid dosage should be avoided.48 As per regular
follow-up, tapering of DMARDs/glucocorticoids may be
considered in patients in persistent remission.50 51 Besides
general measures, patients may be counselled to stay at
home whenever possible, use surgical masks when going
out, stay physically and mentally active, eat healthily, rest
frequently and cultivate sleep hygiene.52 Distance support
over telephone/video consultation can be offered, along
with a direct contact (secure phone/email) to the
department/rheumatologist.20 It is important that patients
are informed of suggestive COVID-19 symptoms and
instructed to report them immediately to the department
and national health authorities. If infected, glucocorticoids
cannot be stopped abruptly and dosage modifications need
to be carefully assessed.20 48 Changes to ongoing DMARD
therapy are best decided on a case-by-case basis, in a shared
decision process.20 Close monitoring of the evolution of
each case ensures patient’s safety and facilitates enrolment
in national/international registers.53 54
Reorganising patient care
Themost challenging aspect of adapting to the pandemic
is, undoubtedly, the reorganisation of patient care. This
may vary depending on local policy, hospital/clinic con-
text, volume of clinical activity and available facilities/
staff. The model herein proposed may be best adapted
to local circumstances.
Outpatient clinic
In this context, remote telehealth consultations of
patients with RMDs under previous follow-up are
preferred.20 48 This aims at assessing clinical symptoms,
evaluating results or need for blood tests, assuring pre-
scriptions, providing psychological support, giving rele-
vant information and scheduling a face-to-face
appointment for a period of expected control of the
pandemic. Patients with disease worsening, treatment
complications or in whom physical evaluation is essential
should discuss with their rheumatologist the risk–benefit
of a face-to-face evaluation.20 48 Likewise, the same atti-
tude is preconised in urgent new outpatient referrals,
including suspicious cases of inflammatory arthritides,
CTDs and vasculitis. Other referrals should be post-
poned. Adequate support from, and collaboration with,
family physicians is crucial in this stage, aiming at shared
care of patients with RMDs.
Management of targeted DMARDs and day care units
Most patients treated with subcutaneous biologic
(bDMARDs) and oral targeted synthetic DMARDs
(tsDMARDs) can be safely monitored over telemedicine,
reducing routine blood tests to the indispensable. Hospi-
tals and national health systems might provide delivery of
these drugs at home or at a local pharmacy, avoiding
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unnecessary travel to the hospital pharmacy. In the case
of intravenous therapies, prioritisation might be neces-
sary. Delaying treatment of patients with active CTDs and
vasculitis with cyclophosphamide, rituximab, tocilizumab
and belimumab may negatively impact the short-term
outcome of these patients. On the contrary, spacing of
infliximab can be a wise option in inflammatory arthritis
patients with adequate disease control.48 For patients with
stable disease activity and treated with intravenous tocili-
zumab, abatacept and belimumab, a discussion on the
switch to subcutaneous formulations may be appropriate.
Other possible strategies to reduce day care activity
include carefully evaluating the spacing or need for intra-
venous immunoglobulin, iloprost (eg, consider phospho-
diesterase-5 inhibitors) and zoledronate. Whenever
reasonable, short-term delay of b/tsDMARDs start may
be considered, excluding patients with vital organ-
threatening disease.48
Specific measures may be necessary to assure the
minimal functioning of day care facilities. Ideally, this
would be in a non-COVID-19 area/building, with treat-
ment schedules adapted to allow safe distancing
(>2 m) at the infusion and waiting rooms, and patients
coming in at a specific hour (when available seats are
expected), wearing surgical masks.12 The use of perso-
nal protective equipment (PPE) adjusted to the possi-
bility of contacting with asymptomatic/presymptomatic
patients with COVID-19 by HCWs would be desirable,
but may be limited by supply shortage.12–15 Frequent
and between-patient disinfection of common surfaces
is important to be observed. Screening of patients for
COVID-19 symptoms and risk contacts prior to treat-
ment (over telephone and on-site), coupled with tem-
perature check and supervised hand sanitising, may
contribute to increase safety. Systematic pre-treatment
SARS-CoV-2 testing is likely not justified, but might be
considered in specific cases (eg, potentially riskful
contacts).
Inpatient admissions
Patient admissions should be reserved for acute, severe
rheumatic manifestations and kept as short as possible.
This will be mostly limited to severe manifestations of
CTDs and vasculitis, and serious adverse effects of
ongoing treatments. Depending on local practice, cases
of infectious arthritis/spondylodiscitis may be admitted
to rheumatology or orthopaedic wards. To account for
presymptomatic/asymptomatic carriers and prevent in-
hospital outbreaks, it would be desirable that all admitted
patients are tested for SARS-CoV-2. Urgent rheumatology
support to other inpatients and to the emergency depart-
ment may be guaranteed by a rotating rheumatologist in
physical presence.
Rheumatological procedures
Diagnostic or therapeutic rheumatological technical pro-
cedures during lockdown are limited to patients that
require undelayable physical evaluation. This mainly
includes suspicions of infectious arthritis/tenosynovitis
(synovial fluid aspiration) and giant cell arteritis (arterial
ultrasound). As for other activities, protective measures
ought to cover the possibility of contacting with asympto-
matic/presymptomatic patients with COVID-19.
Paediatric rheumatology
The care of paediatric rheumatic patients can follow the
same framework already described but does have a few
singularities. There is a more frequent need for physical
examination of new referrals and children with changes
in symptom pattern, as reported by parents via phone
consultation. Aiming at reducing circulating persons in
healthcare facilities, it would be preferable if only one of
the parents (or family member/legal guardian) is present
in face-to-face appointments, infusion rooms or rheuma-
tological procedures, following on-site evaluation of
COVID-19 symptoms, temperature and hand sanitising.
Surgical masks are required for all participants in the
visits, except for children under 2 years of age.12–15 55
However, scaling PPE to account for presymptomatic/
asymptomatic COVID-19 cases may be considered in chil-
dren difficult to examine, who often cry and cough,
releasing respiratory droplets. Testing children prior to
admission or to joint procedures performed under gen-
eral anaesthesia or nitrous oxide sedation is desirable.
DAY-AFTER: ADAPTING TO A LINGERING PANDEMIC
Following the initial lockdown phase, we will have to deal
with the COVID-19 threat for months to come. It is clearly
unsustainable to maintain distance follow-up of patients
with RMDs in the long run. Thus, adequate preparation
and anticipation of the ‘day-after’ in rheumatology prac-
tice is needed, as restrictive measures are slowly lifted, but
themenace of COVID-19 remains. If not larger, this will at
least be as great an effort as the one detailed earlier. The
long period it covers, along with the uncertainty asso-
ciated, will test patients, physicians and other HCWs
alike, to a degree we cannot yet clearly define.
What about immunity?
At present, most relevant questions regarding immunity
developed to SARS-CoV-2 are largely unanswered and,
thus, maximal caution is advised.56 As serological assays
become available, patients and HCWs can be tested to
identify those who have developed an immunological
response.57 This may include the identification of cases
of asymptomatic infection or false-negative RT-PCR.57–59
While it is expected that most COVID-19 patients develop
some kind of immune response, it has been shown that
antibody titres can be of limited magnitude in up to 30%
of cases and absent in up to 6%.60 Also, it is not clear if
existing IgG antibodies are always protective, at what titre,
and for how long.56 57 Nor is it known if the severity of
infection influences the degree of immune response.25 61
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The impact of other factors such as age, sex, comorbid-
ities and concomitant immunosuppressive therapy is also
completely unknown and may play a role in patients with
RMDs.56
For these reasons, careful interpretation of serology
results needs to be ensured. Screening of HCWs in direct
contact with suspected or confirmed patients with
COVID-19 may be appropriate. However, a positive anti-
SARS-CoV-2 IgG does not justify, at the moment, chan-
ging the level of care or preventive measures by HCWs
and patients. In particular, the immunological result to
SARS-CoV-2 does not validate HCWs being assigned to
different clinical tasks.
Resuming on-site clinical care
As of now and in upcoming months, on-site clinical care
of patients with RMDs needs to be resumed. This will
likely prove the greatest challenge of all, as it will still be
a far different reality from what we were used to. In
a phased, systematised way, patients will have to return
to face-to-face consultations. Those with urgent referrals,
active disease, serious manifestations or clear distance
communication barriers may take priority. Initiation of
b/tsDMARDs can be programmed, and selected common
technical procedures (eg, elective joint injections/aspira-
tions) slowly scheduled. It is also important to guarantee
that pending laboratory tests and other complementary
exams are progressively performed. Finally, admission
criteria for face-to-face consultations may be progressively
widened. The nature and pace of thesemeasures will vary,
depending on local realities and pandemic evolution.
A few specific practical measures can be put forward.
Waiting room capacity should allow safe intervals
between patients and match the number of working con-
sultation rooms. Extension of outpatient clinic working
hours (eg, 8:00–20:00) may enable distribution of attend-
ing periods throughout the day. Patients are encouraged
to come unaccompanied and at the precise time of the
appointment. Physicians, in turn, should be compliant
with set agendas and fixed consultation slots (eg,
30 min). Further, it would be desirable that each clinician
avoids extending clinic periods for long consecutive
hours, to prevent fatigue and the consequent risk of
neglecting safety procedures. Protective measures for
patients and HCWs are likely to remain the same as
those described earlier. In addition, testing for SARS-
CoV-2 may be justified prior to procedures such as
minor salivary gland biopsies.
A pronounced bottleneck effect is to be expected. This
results from several factors, including the delayed care of
patients already under follow-up, the 2-months halt in
new non-urgent referrals, as well as the slower pace of
care as it is resumed. As such, patience, resilience and
creativity are going to be in great demand for all of us in
this period. In addition, the whole system may be tested
further as potential additional contagion waves arise. Fol-
lowing the control of the first outburst and as restrictions
are being softened, it is possible—and in fact expectable
—that a rise in cases and community transmission is
observed. The extent of this upsurge is to be determined,
but it may well grow enough to justify reinstitution of
regional or national lockdown and, as a consequence, of
the clinical measures described earlier. Such an on-and-
off approach is likely to place too heavy a toll on the
health system, HCWs and patients, the consequences of
which we cannot even foresee.
Keeping research, training and education going
While most attention is naturally placed in minoring the
clinical consequences in the care of patients with RMDs,
one cannot forget the importance of maintaining clinical
and translation research activities, and assuring under-
graduate and postgraduate medical training.62 64
Clinical trials and observational studies are key to
advancing the knowledge of all aspects of RMDs. More-
over, there has been tremendous investment in effort and
resources that cannot be wasted. It is thus vital that clin-
icians, patients and researchers work together to ensure
patient retention and slowly resume patient recruitment
and the set-up of new studies.62 65 Innovative trials, espe-
cially phase I/II, are likely to encounter additional reluc-
tance from patients, who might be wary of potential side
effects and increased vulnerability to COVID-19. Fre-
quent visits and travel to the hospital may be yet another
setback for patient inclusion. In this regard, investigators
play an essential role in keeping patient safety as the
utmost priority, while minimising loss to follow-up and
missing data. Specific on-site measures similar to the
described earlier may be necessary as part of a COVID-
19 action plan. Academic and industry sponsors should
consider minor protocol amendments, such as allowing
remote assessments, limiting non-essential visits, incor-
porating regular SARS-CoV-2 testing during trials and
extending recruitment periods.62 65 Collaborative work
involving all parties is needed more than ever to keep
research ongoing.
Preclinical and clinical medical training and education
have also been severely disrupted by the pandemic. Glob-
ally, medical schools were forced to close and started
online teaching on short-notice, aiming to protect both
students and patients, but greatly affecting clinical prac-
tice training.63 Likewise, speciality training was halted for
2–3months, as routine clinical work stopped and trainees
were enrolled in COVID-19-centred teams, while still col-
laborating in telemedicine activities.64 As patient care is
progressively resumed, trainees may be incorporated in
previous rotations, developing supervised clinical work in
outpatient, inpatient, day care and rheumatological pro-
cedures settings. Speciality training programmes may
need to be extended to compensate for the break in
specific formation.64 Accompanying consultants in
patient visits may no longer be wise, to avoid overcrowd-
ing. This will prove particularly challenging for under-
graduate rheumatology training, requiring low student-to
-patient ratios. It may require profound reorganisation of
medical curricula, extending clinical rotations for longer
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periods, to allow for better student distribution through-
out the year.63
LOOKING AHEAD: POST-COVID-19 RHEUMATOLOGY
As the post-pandemic era is still little more than a mirage,
society in general and healthcare in particular should not
shy away from taking valuable lessons from these unprece-
dented events. The post-COVID-19 period will hardly be
the same as it was up to early 2020, and the field of RMDs is
no exception. It is our responsibility to quickly begin
thinking about it and incorporate strategies that will slowly
change the way we currently practise rheumatology.
It is important to first acknowledge the potential of
telemedicine, including telephone and video
consultations.66 At least a part of routine follow-up visits
may easily be adapted to this form, saving unnecessary
patient travel, while still assuring care. To assure this,
optimal communication and cooperation between rheu-
matologists and family medicine physicians is of para-
mount importance.67 We will have the unique
opportunity to consolidate shared care as standard prac-
tice for patients with RMDs. Simply allowing patients to
do blood tests or imaging exams in ambulatory clinics
may greatly reduce patient flow and accumulation in
common hospital areas. Simultaneously, reinforcing
patient and HCW education in fundamental preventive
gestures, such as frequent hand washing, social distan-
cing and symptommonitoring will aid reducing transmis-
sion of this and other infectious diseases. Assurance of
safe, large, adequate healthcare facilities for outpatient,
inpatient and day care is important to remain the norm
after the pandemic fades. Clinical and scientific regular
meetings can be reassessed for the need of physical pre-
sence and optimised to reduce wasteful time. In particu-
lar, classical ward rounds may have to be reassessed for
their learning potential and progressively abandoned to
comply with precautionary measures. Protection of
HCWs in terms of long hours, agenda burden, patient
overbooking and bureaucratic tasks needs to be
observed. Alternatives are required to physician and
researcher travel to short meetings, taking advantage of
digital web conferencing tools.
CONCLUSIONS
The COVID-19 pandemic has brought tremendous chal-
lenges upon rheumatologists and patients with RMDs.
Together, we have so far been able to adapt to such
exceptional circumstances and respond in a fast, effective
fashion to secure immediate clinical care. As lockdowns
start to be removed, we will be faced with novel demands,
that will test us and our institutions for a long period.
Hopefully, we can minimise the impact of this common
opponent, learn and grow from the struggle. The future
in rheumatology will, undoubtedly, be influenced by this
event and we all have a role to play in designing it, starting
from today.
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